Oral neratinib: Updated Ph II SUMMIT data

Data from 24 evaluable metastatic breast cancer patients with an activating HER2 mutation in the open-label, international Phase II SUMMIT trial showed that once-daily 240 mg oral neratinib plus loperamide prophylaxis for the first

Read the full 343 word article

User Sign In